Evidence-Based Medicine Online First, published on March 26, 2015 as 10.1136/ebmed-2015-110168
Therapeutics
Randomised controlled trial
Nebulised hypertonic saline does not reduce hospital length of stay in acute bronchiolitis 10.1136/ebmed-2015-110168
Todd A Florin Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA Correspondence to: Dr Todd A Florin, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML 2008, Cincinnati, OH 45229, USA; [email protected]
Commentary on: Everard ML, Hind D, Ugonna K, et al. SABRE: a multicenter randomized control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax 2014;69:1105–12.
Context Acute bronchiolitis is the most frequent lower respiratory infection in infancy, yet no therapy has shown consistent benefit.1 Although initially promising, there is now conflicting evidence regarding the efficacy of nebulised 3% hypertonic saline (HS). In 2013, a Cochrane meta-analysis concluded that HS may significantly reduce the hospital length of stay among infants hospitalised with mild-to-moderate bronchiolitis and also improve clinical severity scores.2 Other studies suggest that HS has no effect on length of stay.3 4
Methods This study was a multicentre, parallel-group, open-label randomised trial comparing 4 mL of nebulised HS administered every 6 h to standard supportive care in infants aged
Therapeutics
Randomised controlled trial
Nebulised hypertonic saline does not reduce hospital length of stay in acute bronchiolitis 10.1136/ebmed-2015-110168
Todd A Florin Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA Correspondence to: Dr Todd A Florin, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, ML 2008, Cincinnati, OH 45229, USA; [email protected]
Commentary on: Everard ML, Hind D, Ugonna K, et al. SABRE: a multicenter randomized control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax 2014;69:1105–12.
Context Acute bronchiolitis is the most frequent lower respiratory infection in infancy, yet no therapy has shown consistent benefit.1 Although initially promising, there is now conflicting evidence regarding the efficacy of nebulised 3% hypertonic saline (HS). In 2013, a Cochrane meta-analysis concluded that HS may significantly reduce the hospital length of stay among infants hospitalised with mild-to-moderate bronchiolitis and also improve clinical severity scores.2 Other studies suggest that HS has no effect on length of stay.3 4
Methods This study was a multicentre, parallel-group, open-label randomised trial comparing 4 mL of nebulised HS administered every 6 h to standard supportive care in infants aged
